Rivastigmine Market: analysis and a holistic overview of the market situations in the forecast period.
Rivastigmine |
Rivastigmine Sandoz is a medication that
contains the active ingredient Exelon. It comes in the form of capsules
(yellow: 1.5 mg; orange: 3 mg; red: 4.5 mg; red and orange: 6 mg) and an oral
solution (2 mg/ml). This medicine is the same as Exelon capsules and oral
solution, which is already approved in the European Union (EU). Exelon's
manufacturer has agreed to allow Exelon Sandoz to use its scientific data.
Rivastigmine
Sandoz is used to treat patients with mild to moderately severe Alzheimer's
dementia, a progressive brain disorder that affects memory, cognitive ability,
and behavior over time. Exelon Sandoz is also used to treat mild to moderately
severe dementia in Parkinson's disease patients. Exelon Sandoz should be
started and monitored by a doctor who has experience diagnosing and treating
Alzheimer's disease or dementia in Parkinson's disease patients. Treatment
should begin only if a caregiver is available to monitor the patient's use of
Exelon Sandoz on a regular basis. Treatment should be continued as long as the
medicine is beneficial, but the dose can be reduced or the treatment stopped if
the patient experiences side effects.
Exelon, the active ingredient in Rivastigmine
Sandoz, is an antidementia medication. Certain nerve cells in the brain die in
patients with Alzheimer's dementia or Parkinson's disease, resulting in low
levels of the neurotransmitter acetylcholine (a chemical that allows nerve
cells to communicate with each other). Exelon works by inhibiting the enzymes
responsible for the breakdown of acetylcholine, acetylcholinesterase, and
butyrylcholinesterase.
Exelon Sandoz works by inhibiting these
enzymes, allowing acetylcholine levels in the brain to rise, aiding in the
treatment of Alzheimer's and Parkinson's disease dementia symptoms. Exelon is a
cholinesterase enzyme inhibitor that inhibits butyl and acetylcholinesterase.
It is a cholinergic agent used to treat Alzheimer's and Parkinson's disease.
Because of its small molecular size, the drug can be administered orally or
through transdermal patches.
Comments
Post a Comment